Insane reason couple facing deportation
Jessica Mathers and Rob O'Leary thought they were living the Australian dream – but in a case of bureaucracy gone mad, the English couple face being booted out of the country after she was diagnosed with an incurable disease.
Now they are appealing for immigration minister Tony Burke to green light their visa and allow them to stay in the country which has become their adopted home.
Their story is similar to so many others – they came from the UK in their 20s seeking sun, adventure, opportunity and everything that Australia has to offer.
They met at a backpackers hostel in 2017, fell in love and decided they wanted to make Australia their home.
In a cruel twist of fate, Jess was diagnosed with Relapsing-Remitting Multiple Sclerosis.
She receives regular treatment and her condition has remained stable, allowing her to work and contribute positively to the community via charity work. British couple Jessica Mathers and Robert O'Leary are facing being kicked out of Australian unless the immigration intervenes in their case. Supplied. Credit: Supplied
Her treatment doesn't cost the Australian taxpayers – because it's covered under Australia's reciprocal healthcare agreement with the UK.
However, it's being used as a reason to block their application for permanent residency because she failed to meet the health requirements.
All visa applicants must meet health requirements, in part to ensure that Australian citizens and permanent residents can access healthcare which is in short supply and to control how much we spend on health services.
Now it's up to the immigration minister to make a decision on whether they will be allowed to remain in the country.
'Jess and Rob are perfect examples of what Australia needs – a young couple who have a lot of potential, already have contributed to Australia in so many ways over the last eight years,' their lawyer Marial Lewis from Crossover Law Group told NewsWire.
The couple – surrounded by a throng of friends and supporters – on Monday afternoon appeared before the Administrative Appeals Tribunal where sought to overturn the immigration department's decision to block their visa.
They were told by Senior Member Kira Raif that their only option was to request a new health test from a second practitioner.
However, the tribunal heard that would do little given Jessica's diagnosis. Immigration minister Tony Burke has the power to intervene in the case on compassionate grounds. NewsWire/Martin Ollman. Credit: News Corp Australia
The next step is to now ask Mr Burke to use his powers to personally intervene in their case.
Support for their cause is evident by the fact that over 22,000 people have now signed a petition calling for them to be allowed to stay.
If they are booted out of the country, Australia will lose two business owners who have dreams of expanding and providing secure jobs for hardworking Aussies.
Rob is a skilled labourer and carpenter and has his own company – O'Leary Cranes and Construction.
Ironically, he wanted to expand and bring on employees. But because of his visa status, he couldn't get a loan from banks to cover a few month's worth of wages.
'We've been here 10 years and I've got dreams, I've got goals over here, goals that are only going to benefit the economy, what I want to do with my business,' Rob said.
'The reason I haven't been able to act on some of my ideas is because I haven't been able to speak to banks … That's actually hindered the Australian economy potentially. We have a vision of what we want to do and that will only benefit the country we live in.'
While Jessica is a whirlwind of energy. She works at a law firm, occasionally moonlights as a nanny, is a part-time DJ and a tireless campaigner for charity. Rob O'Leary. Credit: Supplied Jessica Mathers. Credit: Supplied
This Friday she's hosting a DJ night and fundraiser for World MS Day at Noir at Darlinghurst.
The couple are currently on bridging visas which are due to expire in approximately a month.
They now hope the minister can use his powers to allow them to stay in Australia.
She says the case is all about her love for Australia, and her and Rob's desire to make it their home.
'If (Mr Burke) gives us a visa, we will continue to contribute positively to the economy and we can offer so much more than we do now,' she said.
'I'm restricted because of my bridging visa – but I still jump from temp job to temp job, I DJ every weekend, I do all the charity work I do.
'But if I had a permanent visa, it would open so many more doors for me. There are so many businesses I've gone to that need permanent residency to work.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
7NEWS
8 hours ago
- 7NEWS
Trailblazing cricket icon David ‘Syd' Lawrence dies of motor neurone disease, aged 61
Former England fast bowler David 'Syd' Lawrence has lost his battle with motor neurone disease (MND) at the age of 61. Lawrence was a trailblazer for international cricket, becoming the first British-born black player to represent England when he debuted in 1988. Since being diagnosed with MND last year, Lawrence has raised significant funds and awareness for the disease, for which he was appointed MBA in the King's Birthday honours earlier this month. BBC radio show Test Match Special shared the news of his death on Sunday night (AEST). 'It is with great sadness we report the passing of David 'Syd' Lawrence,' they said. 'Syd, the first British-born black cricketer to represent England, was diagnosed with motor neurone disease last year. He has died at the age of 61. 'The former fast bowler will forever be an England and Gloucestershire legend. 'Our thoughts are with his family and friends, as well as everyone impacted by this horrible disease. Rest peacefully, Syd.' A family statement read: 'Syd was an inspirational figure on and off the cricket field and no more so than to his family who were with him when he passed.' Lawrence played five Tests for England, taking three wickets on debut against Sri Lanka, and 18 in total. In England though, he was better known for his decorated career at Gloucestershire, where he took 477 wickets at 31.27 in 170 first-class matches for the county. 'A proud Gloucestershire man, Syd took on every challenge with everything he could and his final contest with MND was no different,' his family added. 'His willingness to encourage and think of others right up to the end was typical of the man he was.' On Sunday, players from England and India observed a minute's applause before play began on Day 3 of the first Test match of their series.
The Advertiser
11 hours ago
- The Advertiser
'Game changer' diabetes pill a step closer after trials
Game-changing diabetes pills could hit Australian shelves within years, offering an alternative to popular injectable treatments like Ozempic that have been plagued with supply issues. That's the prediction from Australian diabetes experts, as the first phase three clinical trial data was released for a new type of medicine that lowers blood sugar. Once-a-day pill Orforglipron was shown to imitate a naturally occurring hormone that helps regulate blood sugar and appetite, according to the study published in the prestigious New England Journal of Medicine. "It's really, really exciting," Australian Diabetes Society chief executive Associate Professor Sof Andrikopoulos told AAP. "The reduction in blood glucose and weight with Orforglipron is similar, if not a little bit better, than the similar clinical trials that were done for Ozempic and Mounjaro." The results of the trials, involving 500 adults with type 2 diabetes, were unveiled at the American Diabetes Association annual meeting in Chicago over the weekend. Reported side effects were similar to existing medications like gastrointestinal issues, while the drug company did not flag any unexpected safety concerns. The trial focused on diabetes treatment and not specifically weight loss. Other oral diabetes medications already exist but this medication is significant as it's the first synthetic treatment to reach phase three trials, Prof Andrikopoulos said. He expected approval from the Therapeutic Goods Administration would be "reasonable straightforward" once it receives an application by drug developer Eli Lilly, which also makes Mounjaro. The synthetic chemical is easier to make than other drugs involving modified peptides and doesn't need to be refrigerated, hoping it would be cheaper and easier to transport to remote areas than injectable treatments. "These are potentially disease modifying therapies, and in that respect it's a game-changer," Prof Andrikopoulos said. "In terms of managing types of diabetes and obesity, I think we are at the cusp of being able to make a significant impact on reducing obesity in Australia and around the world." Sydney-based Endocrinologist Associate Professor Ted Wu treats many patients with diabetes and said physicians had been "crying out" for oral alternatives to incretin injections. While optimistic about the findings, he cautioned it was not a "head to head" trial measuring the effectiveness of Orforglipron against injections but said it appears the results were very similar. "As it stands, this looks like it offers all the advantages of the current incretin injections, but with all the advantages of an oral once-a-day medication and hopefully with far fewer supply issues," he said. Prof Wu said looking at past performance, the TGA would probably take between 12 and 24 months to approve the new drug. Game-changing diabetes pills could hit Australian shelves within years, offering an alternative to popular injectable treatments like Ozempic that have been plagued with supply issues. That's the prediction from Australian diabetes experts, as the first phase three clinical trial data was released for a new type of medicine that lowers blood sugar. Once-a-day pill Orforglipron was shown to imitate a naturally occurring hormone that helps regulate blood sugar and appetite, according to the study published in the prestigious New England Journal of Medicine. "It's really, really exciting," Australian Diabetes Society chief executive Associate Professor Sof Andrikopoulos told AAP. "The reduction in blood glucose and weight with Orforglipron is similar, if not a little bit better, than the similar clinical trials that were done for Ozempic and Mounjaro." The results of the trials, involving 500 adults with type 2 diabetes, were unveiled at the American Diabetes Association annual meeting in Chicago over the weekend. Reported side effects were similar to existing medications like gastrointestinal issues, while the drug company did not flag any unexpected safety concerns. The trial focused on diabetes treatment and not specifically weight loss. Other oral diabetes medications already exist but this medication is significant as it's the first synthetic treatment to reach phase three trials, Prof Andrikopoulos said. He expected approval from the Therapeutic Goods Administration would be "reasonable straightforward" once it receives an application by drug developer Eli Lilly, which also makes Mounjaro. The synthetic chemical is easier to make than other drugs involving modified peptides and doesn't need to be refrigerated, hoping it would be cheaper and easier to transport to remote areas than injectable treatments. "These are potentially disease modifying therapies, and in that respect it's a game-changer," Prof Andrikopoulos said. "In terms of managing types of diabetes and obesity, I think we are at the cusp of being able to make a significant impact on reducing obesity in Australia and around the world." Sydney-based Endocrinologist Associate Professor Ted Wu treats many patients with diabetes and said physicians had been "crying out" for oral alternatives to incretin injections. While optimistic about the findings, he cautioned it was not a "head to head" trial measuring the effectiveness of Orforglipron against injections but said it appears the results were very similar. "As it stands, this looks like it offers all the advantages of the current incretin injections, but with all the advantages of an oral once-a-day medication and hopefully with far fewer supply issues," he said. Prof Wu said looking at past performance, the TGA would probably take between 12 and 24 months to approve the new drug. Game-changing diabetes pills could hit Australian shelves within years, offering an alternative to popular injectable treatments like Ozempic that have been plagued with supply issues. That's the prediction from Australian diabetes experts, as the first phase three clinical trial data was released for a new type of medicine that lowers blood sugar. Once-a-day pill Orforglipron was shown to imitate a naturally occurring hormone that helps regulate blood sugar and appetite, according to the study published in the prestigious New England Journal of Medicine. "It's really, really exciting," Australian Diabetes Society chief executive Associate Professor Sof Andrikopoulos told AAP. "The reduction in blood glucose and weight with Orforglipron is similar, if not a little bit better, than the similar clinical trials that were done for Ozempic and Mounjaro." The results of the trials, involving 500 adults with type 2 diabetes, were unveiled at the American Diabetes Association annual meeting in Chicago over the weekend. Reported side effects were similar to existing medications like gastrointestinal issues, while the drug company did not flag any unexpected safety concerns. The trial focused on diabetes treatment and not specifically weight loss. Other oral diabetes medications already exist but this medication is significant as it's the first synthetic treatment to reach phase three trials, Prof Andrikopoulos said. He expected approval from the Therapeutic Goods Administration would be "reasonable straightforward" once it receives an application by drug developer Eli Lilly, which also makes Mounjaro. The synthetic chemical is easier to make than other drugs involving modified peptides and doesn't need to be refrigerated, hoping it would be cheaper and easier to transport to remote areas than injectable treatments. "These are potentially disease modifying therapies, and in that respect it's a game-changer," Prof Andrikopoulos said. "In terms of managing types of diabetes and obesity, I think we are at the cusp of being able to make a significant impact on reducing obesity in Australia and around the world." Sydney-based Endocrinologist Associate Professor Ted Wu treats many patients with diabetes and said physicians had been "crying out" for oral alternatives to incretin injections. While optimistic about the findings, he cautioned it was not a "head to head" trial measuring the effectiveness of Orforglipron against injections but said it appears the results were very similar. "As it stands, this looks like it offers all the advantages of the current incretin injections, but with all the advantages of an oral once-a-day medication and hopefully with far fewer supply issues," he said. Prof Wu said looking at past performance, the TGA would probably take between 12 and 24 months to approve the new drug. Game-changing diabetes pills could hit Australian shelves within years, offering an alternative to popular injectable treatments like Ozempic that have been plagued with supply issues. That's the prediction from Australian diabetes experts, as the first phase three clinical trial data was released for a new type of medicine that lowers blood sugar. Once-a-day pill Orforglipron was shown to imitate a naturally occurring hormone that helps regulate blood sugar and appetite, according to the study published in the prestigious New England Journal of Medicine. "It's really, really exciting," Australian Diabetes Society chief executive Associate Professor Sof Andrikopoulos told AAP. "The reduction in blood glucose and weight with Orforglipron is similar, if not a little bit better, than the similar clinical trials that were done for Ozempic and Mounjaro." The results of the trials, involving 500 adults with type 2 diabetes, were unveiled at the American Diabetes Association annual meeting in Chicago over the weekend. Reported side effects were similar to existing medications like gastrointestinal issues, while the drug company did not flag any unexpected safety concerns. The trial focused on diabetes treatment and not specifically weight loss. Other oral diabetes medications already exist but this medication is significant as it's the first synthetic treatment to reach phase three trials, Prof Andrikopoulos said. He expected approval from the Therapeutic Goods Administration would be "reasonable straightforward" once it receives an application by drug developer Eli Lilly, which also makes Mounjaro. The synthetic chemical is easier to make than other drugs involving modified peptides and doesn't need to be refrigerated, hoping it would be cheaper and easier to transport to remote areas than injectable treatments. "These are potentially disease modifying therapies, and in that respect it's a game-changer," Prof Andrikopoulos said. "In terms of managing types of diabetes and obesity, I think we are at the cusp of being able to make a significant impact on reducing obesity in Australia and around the world." Sydney-based Endocrinologist Associate Professor Ted Wu treats many patients with diabetes and said physicians had been "crying out" for oral alternatives to incretin injections. While optimistic about the findings, he cautioned it was not a "head to head" trial measuring the effectiveness of Orforglipron against injections but said it appears the results were very similar. "As it stands, this looks like it offers all the advantages of the current incretin injections, but with all the advantages of an oral once-a-day medication and hopefully with far fewer supply issues," he said. Prof Wu said looking at past performance, the TGA would probably take between 12 and 24 months to approve the new drug.
AU Financial Review
12 hours ago
- AU Financial Review
‘Game changer' diabetes pill a step closer after trials
Game-changing diabetes pills could hit Australian shelves within years, offering an alternative to popular injectable treatments such as Ozempic that have been plagued with supply issues. That's the prediction from Australian diabetes experts, as the first phase three clinical trial data was released for a new type of medicine that lowers blood sugar. AAP
